Abstract 20P
Background
In China, new breast cancer (BC) patients (pts) in county regions (including rural areas) account for more than 40% of all BC cases each year. No studies have reported the disease characteristics and treatment patterns of BC pts in China counties. This study aimed to explore the treatment patterns of BC pts in county-level hospitals in China.
Methods
CHASE001 was an observational, multicenter study assessing real-world treatment patterns among pts with HER2+ or HR+/HER2- BC conducted at 26 sites in county areas of China, including four cohorts (HER2+ early BC (eBC), HR+/HER2- eBC, HER2+ advanced BC (aBC), and HR+/HER2- aBC). The primary endpoint was treatment patterns within each cohort. The interim results for HER2+ eBC and HR+/HER2- eBC are described here.
Results
628 pts were included (302 in HER2+ eBC and 326 in HR+/HER2- eBC cohort): for HER2+ and HR+/HER2- cohort respectively, median age, 53/51 years; clinical T2, 41.39%/37.73%; clinical N0, 41.72%/45.40%. Of 584 pts who underwent breast cancer surgery, only 10.53% (30/285) received breast-conserving surgery (BCS) in HER2+ and 12.71% (38/299) in HR+/HER2- cohort. Notably, the proportions of adjuvant radiotherapy (RT) following BCS were 46.67% (14/30) in HER2+ and 47.37% (18/38) in HR+/HER2- cohort. In HER2+ cohort, 20.20% (61/302) received neoadjuvant therapy (NAT) while 94.70% (286/302) received adjuvant therapy. 81.97% (50/61) of NAT were HER2 targeted regimens, of which 84.00% (42/50) received dual anti-HER2 target therapy (trastuzumab/pertuzumab). 80.77% (231/286) of adjuvant therapies were HER2 targeted regimens, of which 53.68% (124/231) were dual-targeted. Of pts with positive lymph nodes who received HER2 targeted adjuvant therapy, 75.90% applied dual anti-HER2 target therapy. In HR+/HER2- cohort, 13.50% (44/326) received NAT while 92.02% (300/326) received adjuvant therapy. The most common neoadjuvant and adjuvant chemotherapy regimens were both AC-T (41.67% and 51.79%, respectively).
Conclusions
This analysis showed unsatisfactory adherence to guidelines for BCS, RT, and NAT, but higher adherence for adjuvant anti-HER2 therapy. Further action was needed to ensure that patients in Chinese county had access to high quality and guideline centric care.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract